Neurology

Previous research shows herpes zoster is associated with a higher long-term risk of subjective cognitive decline, with increased risk for men who carried APOE ε4.

Investigators found that zonisamide was associated with a reduction in monthly migraine days for pediatric populations.

Patients preferred ultrasound stimulation, followed by magnetic stimulation, drugs, electrical stimulation, and brain implantations.

The FDA also granted priority review, with a Prescription Drug User Fee Act target action date of August 19, 2025.

The tablet formation of risdiplam (Evrysdi) demonstrates bioequivalence to the oral formulation of the drug.

The designation is based on the AMULET phase 2 trial, which was the first-in-human study of the drug.

Data has shown the investigational cell therapy is well-tolerated in patients and showed preliminary impacts on cognition.

The drug will be made available in the second quarter of 2025.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

In the TEMPO-1 trial, both tavapadon doses effectively reduced motor symptoms in patients with early-stage Parkinson's disease.

Bezisterim acts on inflammatory signaling pathways and may be a viable treatment option for post–COVID-19 condition, or long COVID.

Results from HERCULES will form the basis for future discussions with global regulatory authorities, according to Sanofi.

In a clinical trial, IPX203 was able to achieve longer good on-time with less doses compared to standard treatment.

Liraglutide slowed the loss of volume in critical brain regions and cognitive decline in patients with mild Alzheimer's dementia.

Researchers addressed the association between semaglutide use and the risk of nonarteritic anterior ischemic optic neuropathy.

Donanemab-azbt was approved under the FDA's Fast Track Review, Priority Review, and Breakthrough Therapy designations.

For Migraine and Headache Awareness Month, Drug Topics spoke with Shivang Joshi, MD, MPH, RPh, FAHS to debunk migraine myths and explore resources to promote migraine awareness and education.

Stimulant medications are the first-line pharmacologic therapy for ADHD, but many of these medications are currently in short supply.

On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.

After facing challenges, Biogen is discontinuing development and sales of aducanumab (Aduhelm) and focusing on lecanemab (Leqembi).